CYP17A1
MOLECULAR TARGETcytochrome P450 family 17 subfamily A member 1
CYP17A1 (cytochrome P450 family 17 subfamily A member 1) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CYP17A1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | bifonazole | 3.71 | 40 |
| 2 | abiraterone | 3.66 | 38 |
| 3 | galeterone | 2.64 | 13 |
| 4 | tioconazole | 2.56 | 12 |
| 5 | azalanstat | 2.20 | 8 |
| 6 | Abiraterone Acetate | 1.10 | 2 |
| 7 | Clotrimazole | 0.69 | 1 |
| 8 | Econazole | 0.69 | 1 |
| 9 | Miconazole | 0.69 | 1 |
| 10 | Testosterone Propionate | 0.69 | 1 |
About CYP17A1 as a Drug Target
CYP17A1 (cytochrome P450 family 17 subfamily A member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented CYP17A1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CYP17A1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.